No Data
Huaxia Ophthalmology (301267): Income steadily growing, waiting for further acceleration.
In the 1-3Q24, the company achieved revenue/net profit attributable to the parent company of 3.182/0.421 billion yuan (yoy +2.6%/-24.5%), with revenue/net profit attributable to the parent company of 1.131/0.155 billion yuan in 3Q24.
Huaxia Ophthalmology: Report for the third quarter of 2024
Huaxia Ophthalmology (301267.SZ): net income in the first three quarters was 0.421 billion yuan, a year-on-year decrease of 24.49%.
Great Wisdom News on October 28th: Huaxia Ophthalmology (301267.SZ) released its third quarter report for 2024, with a company's revenue of 3.182 billion yuan for the first three quarters, a year-on-year increase of 2.55%; net income attributable to the company's shareholders was 0.421 billion yuan, a year-on-year decrease of 24.49%; net income attributable to the company's shareholders after deducting non-recurring gains and losses was 0.417 billion yuan, a year-on-year decrease of 27.23%; basic earnings per share were 0.50 yuan.
Huaxia Ophthalmology (301267): Consumer ophthalmology supports steady revenue growth and nationwide chain layout.
The company released its 2024 interim report, with a revenue of 2.051 billion yuan (YoY +2.85%), and a net income attributable to the parent company of 0.265 billion yuan (YoY -25.15%). National chain layout to consolidate scale effects.
Huaxia Eye (301267): Short-term performance under pressure, long-term growth can be expected.
Event: On August 28, the company released its 2024 interim report, achieving revenue of 2.05 billion yuan in the first half of the year, +2.85% YoY, and achieving a net income attributable to shareholders of 0.265 billion yuan, -25.15% YoY.
Huaxia Ophthalmology: Semi-Annual Report 2024
No Data
No Data